Dr. Robert Arthur Lalane III, MD

Dr. Lalane practices at Retina Group Of Florida in Fort Lauderdale, Florida.

Dr. Lalane's NPI, 1548553431, was assigned on May 25, 2011. Dr. Lalane graduated from Duke University School Of Medicine in 2011. Dr. Lalane holds Florida license ME137441.

Dr. Lalane's primary practice is Retina Group of Florida, at 6333 N Federal Hwy Ste 300 Suite 300, Fort Lauderdale, FL 33308. The practice phone is (954) 776-6880.

Dr. Lalane's primary practice is Retina Group Of Florida in Fort Lauderdale, Florida. The medical group on file is Harbor-UCLA Medical Center. Dmand AI also links Dr. Lalane to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lalane practices. Vendor and product names are available with a free account.

Retina specialist is Dr. Lalane's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Lalane is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Lalane's licenses on file in 4 states: Florida, California, Georgia and South Carolina.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, dry eye, eye infection or inflammation, eyelid inflammation, glaucoma and hereditary corneal conditions among the conditions Dr. Lalane treats.

CMS data shows 37,418 Medicare services from Dr. Lalane across 21 procedure codes in 2024, for 1,012 Medicare patients. Medicare paid $2,742,576 for them.

CMS counts 1,012 Medicare patients who saw Dr. Lalane in 2024. The largest group is 75 to 84, with 426 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lalane's median patient age at 72, with 54% women.

In 2024, Dr. Lalane wrote 632 Medicare Part D claims for 222 patients. 61% of them were for generic drugs. CMS names the drug for 572 of them, across 12 drugs with 11 or more claims each, at $23,883 in total drug cost. In 2023, CMS named 502 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Lalane for performance year 2024, reported as part of a group. Dr. Lalane accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 6 papers to Dr. Lalane, published from 2011 to 2020. The most frequent topics are Choroid, Fluorescein Angiography and Fundus Oculi. Dr. Lalane's most frequent co-authors are Aaron Nagiel, MD, PhD, David Sarraf, MD and Pratap Challa, MD.

CMS Open Payments shows 125 general payments to Dr. Lalane from 18 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 81% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $3,333.

Dmand AI lists 1 award for Dr. Lalane, most recently AOA Inductee 2011 in 2011.

Dr. Lalane graduated from Duke University School Of Medicine in 2011. Dr. Lalane is a member of AOA.

Dr. Lalane is in network with 17 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.